A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
About this item
Full title
Author / Creator
Du, Xuexiang , Tang, Fei , Liu, Mingyue , Su, Juanjuan , Zhang, Yan , Wu, Wei , Devenport, Martin , Lazarski, Christopher A , Zhang, Peng , Wang, Xu , Ye, Peiying , Wang, Changyu , Hwang, Eugene , Zhu, Tinghui , Xu, Ting , Zheng, Pan and Liu, Yang
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
It is assumed that anti-CTLA-4 antibodies cause tumor rejection by blocking negative signaling from B7-CTLA-4 interactions. Surprisingly, at concentrations considerably higher than plasma levels achieved by clinically effective dosing, the anti-CTLA-4 antibody Ipilimumab blocks neither B7 trans-endocytosis by CTLA-4 nor CTLA-4 binding to immobilize...
Alternative Titles
Full title
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5939050
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5939050
Other Identifiers
ISSN
1001-0602
E-ISSN
1748-7838
DOI
10.1038/s41422-018-0011-0
